source
- Hengrui and Kailera's oral GLP-1 pill shows promising efficacy but notable side effects in Chinese obesity and diabetes trialsHengrui Pharma and Kailera Therapeutics reported results from two late‑stage trials in China, one targeting obesity and the other diabetes, using their daily oral GLP‑1 pill. The studies demonstrat…
- STAT+ warns that employer-sponsored health insurance is deteriorating, leaving workers and businesses exposedBob Herman's latest STAT+ newsletter introduces a new series called Out of Pocket, Out of Reach, which will examine how the employer-based health-insurance system is falling apart. The article not…